Peptide·map backed
ATLPC0007174
ATLPC0007174
GFGMAlKLLKKVL
- Length13 aa
- Monoisotopic mass1416.9 Da
Stack
ATLPC0007174
GFGMAlKLLKKVL
Is the peptide identity interpretable at sequence or structure-string level?
Are molecular graph, topology, or 3D coordinates available?
Can basic developability descriptors be computed?
Is this peptide linked to approved or named product context?
What evidence describes systemic exposure or absorption?
What is known about distribution, binding, permeability, or barrier crossing?
How stable is the peptide in biological matrices or protease systems?
What evidence describes clearance or persistence?
What safety, toxicity, or tolerability evidence is attached?
Can every measurement be reviewed in one cross-domain table?
Can the peptide identity be checked against reported names, sequence notation, and reference links?
Can this profile view be reproduced from structured records?
Reviewed sequence, HELM, or SMILES representation used to interpret this peptide identity.
Molecular graph, chemical representation, 3D references, and covalent topology when available.
Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity.
Product-level route, label, and clinical context that frames peptide-level evidence.
What safety, toxicity, or tolerability evidence is attached?
Cross-domain evidence distribution, traceability, and measurement-level detail for this peptide.
Reference-level support for checking reported names, sequence notation, and peptide identity agreement.
Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.
Reported sequence notation was converted to parent-residue display for visualization; the original notation remains shown below.
Features are shown only when a reported notation or topology record supports them.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
Polymer notation suitable for modified peptide and conjugate representation when available.
GFGMAL{d}KLLKKVL{ct:Amid}Chemical graph representation for chemistry-aware interpretation when available.
CSCC[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)CN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C
| PEPstrMOD model |
| predicted |
| 13 aa |
| Open | PEPstrMOD model | predicted | 13 aa |
| Open | PEPstrMOD model | predicted | 13 aa |
Grouped composition is often more interpretable than a long amino-acid list.
The projection assumes an α-helix conformation; a long μH arrow indicates an amphipathic helix, common in antimicrobial peptides.
3 Ro5 violations · MW 1,417.87 Da
The same three research-facing layers are used across ADMETatlas.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 177 μM | Comparable | general | Not specified | Open |
| 2 | 160 μM | Comparable | general | Not specified | Open |
| 3 | > 200 μM | Comparable | general | Not specified | Open |
| 4 | 152 μM | Comparable | general | Not specified | Open |
| 5 | > 200 μM | Comparable | general | Not specified | Open |
| 6 | > 200 μM | Comparable | general | Not specified | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 18 % | Comparable | Human keratinocytes HaCat · Human keratinocytes HaCat · human | Not specified | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 87 μM | Comparable | Human umbilical vein endothelial cells HUVEC · Human umbilical vein endothelial cells HUVEC · human | Not specified | Open |
| 2 | 21 μM | Comparable | Human umbilical vein endothelial cells HUVEC · Human umbilical vein endothelial cells HUVEC · human | Not specified | Open |
| 3 | 56 μM | Comparable | Human umbilical vein endothelial cells HUVEC · Human umbilical vein endothelial cells HUVEC · human | Not specified | Open |
| 4 | 52 μM | Comparable | Human umbilical vein endothelial cells HUVEC · Human umbilical vein endothelial cells HUVEC · human | Not specified | Open |
| 5 | 21 μM | Comparable | Human umbilical vein endothelial cells HUVEC · Human umbilical vein endothelial cells HUVEC · human | Not specified | Open |
| 6 | 28 μM | Comparable | Human umbilical vein endothelial cells HUVEC · Human umbilical vein endothelial cells HUVEC · human | Not specified | Open |
| 7 | 75 μM | Comparable | Rat epithelial cells IEC-6, CRL-1592 · Rat epithelial cells IEC-6, CRL-1592 · rat | Not specified | Open |
| 8 | 27 μM | Comparable | Rat epithelial cells IEC-6, CRL-1592 · Rat epithelial cells IEC-6, CRL-1592 · rat | Not specified | Open |
| 9 | 28 μM | Comparable | Rat epithelial cells IEC-6, CRL-1592 · Rat epithelial cells IEC-6, CRL-1592 · rat | Not specified | Open |
| 10 | > 100 μM | Comparable | Rat epithelial cells IEC-6, CRL-1592 · Rat epithelial cells IEC-6, CRL-1592 · rat | Not specified | Open |
The identity reference does not expose a sequence string.
GFGMAlKLLKKVL
GFGMAlKLLKKVL
Endpoint-level measurements attached to this peptide, suitable for review or reanalysis.
Nested peptide record for scripted retrieval, including identity and evidence context.